Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma: Potential to reduce the tumor recurrence rates and/or improve overall survival

Medical Hypotheses

Volumn 76, Issue 3, 2011, Pages 457-459

  Xu, Jing ^a   Liu, Li ^a   Tang, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CYTOTOXIC AGENT; HEPATITIS B ANTIGEN; HEPATITIS B VIRUS X PROTEIN; NUCLEOTIDE DERIVATIVE; SERUM ALBUMIN; THYMOSIN ALPHA1; VIRUS DNA;

ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR IMMUNITY; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; LETTER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; MORTALITY; OVERALL SURVIVAL; PROGNOSIS; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; T LYMPHOCYTE; TUMOR RECURRENCE; VIRUS CELL INTERACTION; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; RECURRENCE; SURVIVAL RATE;

HEPATITIS B VIRUS;

EID: 79751529779     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.12.016     Document Type: Letter

References (41)

1. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
2. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
3. Ince N., Wands J.R. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999, 340:798-799.
4. El-Serag H.B., Davila J.A., Petersen N.J., McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States - an update. Ann Intern Med 2003, 139:817-823.
5. Corey Kathleen E., Pratt Daniel S. Review: current status of therapy for hepatocellular carcinoma. Ther Adv Gastroenterol 2009, 2:45-57.
6. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000, 32:1224-1229.
7. Feitelson M.A., Sun B., Satiroglu Tufan N.L., Liu J., Pan J., Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002, 21:2593-2604.
8. Lok A.S. Prevention of hepatitis B virus related hepatocellular carcinoma. Gastroenterology 2004, 127:S303-S309.
9. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39 [Erratum, Hepatology 2007;45:1347].
10. Dienstag Jules L. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
11. Na T.Y., Shin Y.K., Roh K.J., Kang S.A., Hong I., et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009, 49:1122-1131.
12. Brechot C. Pathogenesis of hepatitis B virus related hepatocellular carcinoma: old and new paradigm. Gastroenterology 2004, 127:S56-S61.
13. Azam F., Koulaouzidis A. Hepatitis B virus and hepatocarcinogenesis. Ann Hepatol 2008, 7:125-129.
14. Feitelson M.A., Duan L.X. Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997, 150:1141-1157.
15. Montaser L.M., Abbas O.M., Saltah A.M., Waked I.A. Circulating AFP mRNA as a possible indicator of hematogenous spread of HCC Cells: a possible association with HBV infection. J Egypt Natl Canc Inst 2007, 19:48-60.
16. Chen C.J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
17. Ohkubo K., Kato Y., Ichikawa T., et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002, 94:2663-2668.
18. Kubo S., Hirohashi K., Tanaka H., et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000, 88:1016-1024.
19. Huang Y., Wang Z., An S., et al. Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol 2008, 80:591-597.
20. Kubo S., Tsukamoto T., Kawai S., et al. Effects of marker for hepatic fibrosis and viral status on recurrence after resection of hepatitis B virus-related hepatocellular carcinoma. Hepatogastroenterology 2003, 50:497-499.
21. Makoto C., Shuhei H., Toshiya K., et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009, 44:991-999.
22. Simonetti J., Bulkow L., McMahon B.J., et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51:1531-1537.
23. Pang R., Tse E., Poon R.T. Molecular pathways in hepatocellular carcinoma. Cancer Lett 2006, 240:157-169.
24. Brechot C., Gozuacik D., Murakami Y., et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000, 10:211-231.
25. Cha C., Dematteo R.P. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005, 19:25-37.
26. Murakami Y., Saigo K., Takashima H., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54:1162-1168.
27. Arbuthnot P., Capovilla A., Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 2000, 15:357-368.
28. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 2001, 36:651-660.
29. Tang H., Oishi N., Kaneko S., Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006, 97:977-983.
30. Peng Z., Zhang Y., Gu W., Wang Z., Li D., Zhang F., et al. Integration of hepatitis B virus X fragment in hepatocellular carcinoma and its effect on the expression of multiple molecules: a key to the cell cycle and apoptosis. Int J Oncol 2005, 26:467-473.
31. Tarn C., Lee S., Hu Y., Ashendel C., Andrisani O.M. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001, 276:34671-34680.
32. Lin Y., Nomura T., Yamashita T., Dorjsuren D., Tang H., Murakami S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res 1997, 57:5137-5142.
33. Block T.M., Mehta A.S., Fimmel C.J., Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22:5093-5107.
34. Wieland S., Thimme R., Purcell R.H., Chisari F.V. Genomic analysis of the host response to hepatitis B virus infection. PNAS 2004, 101:6669-6674.
35. Nan L., Eric C.H.L., Jie S., et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010, 17:179-185.
36. Kuzuya T., Katano Y., Kumada T., et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007, 22:1929-1935.
37. Masahiko K., Takakazu N., Tomomitu M., et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 2009, 48:11-17.
38. Ruo-Yu M., Hai-Tao Z., Hua-Yu Y., et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010, 16:2931-2942.
39. Kawano Y., Sasaki A., Kai S., et al. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol 2009, 35:174-179.
40. Shuqun C., Mengchao W., Han C., et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006, 53:249-252.
41. Sun H.C., Tang Z.Y., Wang L., et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006, 132:458-465.